Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660648 | 0.87 | REN (0.55) | RENSLC6A4CYP3A4 | |
| SCHEMBL663699 | 0.85 | REN (0.77) | RENCYP3A4 | |
| SCHEMBL664824 | 0.79 | SLC6A4 (0.43) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL662733 | 0.78 | REN (0.53) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL8171105 | 0.72 | SLC6A4 (0.59) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL663164 | 0.71 | REN (1.00) | RENCYP3A4 | |
| SCHEMBL662936 | 0.69 | REN (0.54) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL662533 | 0.69 | SLC6A4 (0.53) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL5072308 | 0.67 | SLC6A4 (0.76) | RENSLC6A4SLC6A2CYP3A4SLC6A3 | |
| SCHEMBL5072329 | 0.67 | SLC6A4 (0.59) | RENSLC6A4SLC6A2CYP3A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885SLC6A4 1352/4885SLC6A2 374/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | REN 1/4885SLC6A4 2577/4885SLC6A2 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.